Millennium Pharmaceuticals, Inc

Feb 23, 09 NEW STORY 15:25 ET Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop      Dec 08, 08 21:32 ET Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma      17:46 ET Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients      Dec 07, 08 20:48 ET Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients      Nov 18, 08 10:33 ET New Data Will Be Presented at ASH on VELCADE(R) (Bortezomib) for Injection-Based Therapies in Multiple Myeloma and Non-Hodgkin's Lymphoma      Oct 22, 08 14:52 ET Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium      Oct 09, 08 14:00 ET Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine      Sep 17, 08 08:00 ET Millennium Hires Two Senior Executives      Aug 27, 08 17:00 ET New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients      Jul 28, 08 08:00 ET Millennium Advances Oncology Pipeline      Jun 20, 08 18:59 ET FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma      May 31, 08 17:37 ET Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma      10:51 ET VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma      May 16, 08 12:50 ET New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma      Apr 29, 08 07:00 ET Takeda and Millennium Announce Early Termination of Hart-Scott-Rodino Waiting Period      Apr 10, 08 02:15 ET Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales      02:06 ET Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion      Mar 17, 08 07:01 ET Millennium Expands IBD Franchise with Addition of New Development Candidate      Mar 13, 08 07:01 ET Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients      Mar 12, 08 08:01 ET Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation      Mar 10, 08 08:01 ET Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation      Feb 28, 08 17:33 ET 2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation      Feb 20, 08 08:45 ET Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma      Feb 07, 08 07:01 ET Millennium Over-Delivers on 2007 Goals and Financial Guidance      Feb 04, 08 16:01 ET BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation      Jan 31, 08 16:01 ET 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation      07:01 ET Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology      Jan 24, 08 16:01 ET Wachovia 2008 Healthcare Conference to Webcast Millennium Presentation   Jan 04, 08 07:01 ET Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results      Jan 02, 08 08:01 ET 26th Annual JPMorgan Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Dec 28, 07 08:01 ET Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection      Dec 27, 07 16:01 ET Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference      Dec 21, 07 07:00 ET Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma      Dec 10, 07 15:02 ET VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial      Dec 09, 07 20:43 ET Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma      17:40 ET Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy      Dec 03, 07 17:27 ET Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event      Nov 26, 07 08:00 ET New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma      Nov 20, 07 16:01 ET BMO Capital Markets Healthcare Conference to Webcast Millennium Presentation      16:01 ET Piper Jaffray 19th Annual Healthcare Conference to Webcast Millennium Presentation      Nov 08, 07 09:04 ET Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders      Nov 06, 07 14:17 ET Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders      Nov 05, 07 16:01 ET 2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation      Nov 01, 07 07:01 ET Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales      Oct 30, 07 10:26 ET CIBC World Markets 18th Annual Healthcare Conference to Webcast Millennium Presentation      Oct 25, 07 09:35 ET Millennium to Webcast Third-Quarter 2007 Financial and Operational Results      Oct 15, 07 09:00 ET FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma      Oct 04, 07 07:01 ET Life Sciences Leader Joins Millennium Board of Directors      Sep 20, 07 16:01 ET UBS Global Life Sciences Conference To Webcast Millennium Presentation      Sep 18, 07 07:01 ET Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints      Sep 13, 07 16:01 ET Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation      Sep 04, 07 08:01 ET Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation      Aug 29, 07 16:01 ET Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation   Aug 15, 07 08:01 ET Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma      Jul 26, 07 07:01 ET Millennium Highlights Strong Second-Quarter Results and Upcoming Growth Catalysts      Jul 19, 07 16:01 ET Millennium to Webcast Second-Quarter 2007 Financial and Operational Results      Jul 16, 07 08:01 ET Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients      Jul 02, 07 08:01 ET VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival      Jun 28, 07 12:00 ET VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications Associated with Multiple Myeloma      11:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma      10:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients      Jun 19, 07 08:01 ET VELCADE(R) (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop      Jun 05, 07 16:01 ET Goldman Sachs 28th Annual Global Healthcare Conference To Webcast Millennium Presentation      Jun 04, 07 15:01 ET New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma      Jun 03, 07 17:46 ET Millennium Introduces New Oncology Molecule with Activity in Broad Range of Cancer Models      15:01 ET VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients      11:01 ET VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients      09:01 ET Millennium Advances Aurora A Kinase Program      Jun 01, 07 08:05 ET Bear Stearns 2007 Biotech Confab To Webcast Millennium Presentation      08:00 ET Millennium Appoints Three New Members to Executive Management Team      May 29, 07 08:01 ET VELCADE(R) (Bortezomib) for Injection to be Featured at Upcoming American Society of Clinical Oncology Meeting      May 24, 07 16:01 ET Bank of America 2007 Healthcare Conference to Webcast Millennium Presentation      May 17, 07 16:01 ET Citigroup 2007 Healthcare Conference to Webcast Millennium Presentation      08:01 ET Millennium Resumes Clinical Program for MLN0002      May 09, 07 16:01 ET Millennium to Webcast 2007 Annual Meeting of Stockholders      May 01, 07 16:00 ET Robert W. Baird 2007 Growth Stock Conference to Webcast Millennium Presentation      Apr 27, 07 16:01 ET Morgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Apr 26, 07 07:01 ET Millennium Reports Strong Financial and Operational Results for First Quarter 2007      Apr 19, 07 16:07 ET Millennium to Webcast First-Quarter 2007 Financial Results      Apr 17, 07 08:05 ET Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection      Apr 06, 07 16:01 ET CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Mar 12, 07 16:01 ET Lehman Brothers Tenth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Mar 07, 07 16:01 ET Cowen and Company 27th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Feb 08, 07 07:01 ET Millennium Exceeds Non-GAAP Profitability Goal and Narrows GAAP Net Loss by 78%(1)      Feb 07, 07 16:11 ET BIO CEO & Investor 2007 Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Feb 01, 07 16:44 ET 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference To Webcast Millennium Pharmaceuticals, Inc. Presentation      Jan 04, 07 16:01 ET Millennium Achieves 2006 Non-GAAP Profitability, Reduces GAAP Net Loss      Jan 02, 07 08:01 ET JPMorgan 25th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 29, 06 09:01 ET Millennium to Webcast Business Update in Advance of 25th Annual JPMorgan Healthcare Conference      Dec 14, 06 08:01 ET Dr. Bob Tepper, President of R&D, to Leave Millennium      Dec 12, 06 16:01 ET VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma      09:00 ET VELCADE(R) (Bortezomib) for Injection Based Therapies Show Consistently High Complete and Near complete Response Rates in Front-Line Multiple Myeloma Trials      Dec 11, 06 16:15 ET VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas      12:00 ET Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma      10:30 ET Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection      Dec 10, 06 16:45 ET VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial      Dec 08, 06 16:41 ET Significant Data on VELCADE(R) (bortezomib) For Injection To Be Presented at Upcoming American Society of Hematology Meeting      Dec 04, 06 09:00 ET Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers      Nov 28, 06 10:15 ET Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis      Nov 22, 06 16:01 ET Piper Jaffray Health Care Conference to Webcast Millennium Presentation      Nov 15, 06 16:01 ET Millennium Closes Sale of $250.0 Million in Convertible Senior Notes      Nov 09, 06 20:02 ET Millennium Prices $225.0 Million in Convertible Senior Notes      06:54 ET Millennium Announces Proposed Offering of $200 Million in Convertible Senior Notes      Nov 02, 06 16:01 ET CIBC World Markets 17th Annual Healthcare Conference to Webcast Millennium Presentation      Oct 30, 06 16:01 ET MassOpps Investment Conference to Webcast Millennium Presentation      Oct 26, 06 07:01 ET Millennium Achieves Non-GAAP Profitability and Reduces GAAP Net Loss for Third Consecutive Quarter(1)      07:00 ET Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection      Oct 19, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Third-Quarter 2006 Financial Results      Oct 17, 06 03:01 ET Millennium Issues Statement Regarding AnorMED Inc.      Oct 06, 06 08:36 ET Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma      Sep 26, 06 09:46 ET Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date      Sep 18, 06 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Presentation      Sep 11, 06 16:06 ET Leerink Swann & Company / MEDACorp Cancer Roundtable Conference to Webcast Millennium Presentation      Sep 05, 06 16:02 ET Bear Stearns 19th Annual Healthcare Conference to Webcast Millennium Presentation      16:01 ET Thomas Weisel Partners Healthcare Conference 2006 to Webcast Millennium Presentation      Aug 30, 06 08:01 ET Millennium Announces Phase I Trial of MLN0415 for Inflammatory Disorders      Aug 09, 06 08:01 ET FDA Grants Priority Review to VELCADE(R) (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma      Jul 27, 06 07:01 ET Millennium Reports Strong Financial Results and Significant Accomplishment Toward 2006 Goals      Jul 26, 06 16:01 ET Baird 2006 Focus on Oncology Conference to Webcast Millennium Presentation      Jul 20, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Second-Quarter 2006 Financial Results      Jun 21, 06 11:55 ET VELCADE(R) (Bortezomib) for Injection Showed Unprecedented Results In Newly Diagnosed Multiple Myeloma Patients      Jun 15, 06 14:21 ET Millennium Responds to Market Report      Jun 09, 06 08:01 ET Millennium Files sNDA for VELCADE(R) (Bortezomib) for Injection in Treatment of Relapsed or Refractory Mantle Cell Lymphoma      Jun 06, 06 16:01 ET Goldman Sachs 27th Annual Healthcare Conference to Webcast Millennium Presentation      Jun 05, 06 14:05 ET Data at ASCO Demonstrate Potential of VELCADE(R) (Bortezomib) for Injection Across Solid and Hematological Cancers      Jun 04, 06 15:35 ET Addition of VELCADE(R) (Bortezomib) for Injection Improved survival in Front-Line Advanced Lung Cancer      10:50 ET VELCADE(R) (Bortezomib) for Injection May Offer New Standard of Care in Relapsed/Refractory Mantle Cell Lymphoma      10:05 ET VELCADE(R) (Bortezomib) for Injection Demonstrated High Single-Agent Response Rates in Newly Diagnosed Multiple Myeloma Patients      May 31, 06 08:01 ET Millennium Announces MLN1202 Fully Met Primary Endpoint in Phase II Clinical Study of Patients at High Risk for Atherosclerosis      May 25, 06 16:01 ET Bear Stearns Biotech Boston Confab to Webcast Millennium Presentation      May 04, 06 16:01 ET Baird 2006 Growth Stock Conference to Webcast Millennium Presentation      Apr 28, 06 16:01 ET Morgan Stanley Global Healthcare Unplugged Conference to Webcast Millennium Presentation      Apr 27, 06 16:01 ET Millennium Pharmaceuticals to Webcast 2006 Annual Meeting of Stockholders      07:01 ET Millennium Achieves First Quarter 2006 Non-GAAP Profitability and Reduces GAAP Net Loss      Apr 20, 06 17:05 ET Millennium Pharmaceuticals to Ring the NASDAQ Opening Bell in Conjunction with First Quarter 2006 Financial Results Conference Call      Apr 18, 06 08:01 ET Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma      Mar 09, 06 08:03 ET Millennium Achieves $10 Million Milestone Payment      Mar 06, 06 08:02 ET Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer      Mar 02, 06 16:01 ET Lehman Brothers Ninth Annual Global Healthcare Conference to Webcast Millennium Presentation   Feb 27, 06 16:01 ET SG Cowen & Co. 26th Annual Health Care Conference to Webcast Millennium Presentation      Feb 17, 06 16:01 ET Citigroup 2006 Healthcare Conference to Webcast Millennium Presentation      Feb 09, 06 08:02 ET Millennium Announces New Senior Vice President of Human Resources      Feb 06, 06 08:03 ET Millennium Announces Pharmaceutical Industry Leader Joins the Board Of Directors      Jan 31, 06 16:01 ET Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Millennium Presentation      Jan 26, 06 07:02 ET Millennium Achieves 2005 Financial Guidance      Jan 25, 06 08:32 ET Millennium Announces Appointments of Executive Vice President of Commercial Operations, Vice President of Finance and Several Key Promotions      Jan 20, 06 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Full-Year 2005 Financial Results      Jan 05, 06 16:01 ET Millennium Details Strategic Drivers for Profitable Growth and 2006 Goals; Highlights 2005 Accomplishments      08:02 ET JPMorgan 24th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 30, 05 08:01 ET Millennium to Webcast Business Update in Advance of 24th Annual JPMorgan Healthcare Conference      Dec 13, 05 09:45 ET Consistently High Complete and Overall Response Rates in Newly-Diagnosed Multiple Myeloma Patients Shown With Velcade(R) (bortezomib) for Injection Based Therapies      Dec 12, 05 18:35 ET VELCADE(R) (bortezomib) for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients      17:39 ET VELCADE(R) (bortezomib) for Injection Continues to Show Impressive Results in a Variety of Lymphomas      Dec 11, 05 09:15 ET New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib) for Injection in Relapsed Multiple Myeloma      Dec 08, 05 16:01 ET Millennium Announces Webcast of Data on VELCADE(R) (Bortezomib) for Injection From the 47th Annual Meeting of the American Society of Hematology      Dec 06, 05 13:41 ET New Data on VELCADE(R) (bortezomib) for Injection to Be Presented at Upcoming American Society of Hematology Meeting      Nov 10, 05 16:01 ET 2005 Credit Suisse First Boston Health Care Conference to Webcast Millennium Presentation      Nov 03, 05 16:27 ET Millennium Initiates Trial of Novel Aurora Kinase Inhibitor MLN8054 in Advanced Solid Tumors      Nov 02, 05 12:00 ET Millennium Announces Clinical Updates at Analyst Day Meeting      Oct 31, 05 16:01 ET CIBC World Markets Sixteenth Annual Healthcare Conference to Webcast Millennium Presentation      Oct 28, 05 16:01 ET MassOpps Investment Conference to Webcast Millennium Presentation      Oct 27, 05 16:10 ET Millennium Announces Webcast of Analyst & Investor Day 2005 Presentations      Oct 26, 05 16:03 ET Millennium Reports Strong Third Quarter 2005 Financial Results      Oct 20, 05 08:01 ET Millennium Senior Vice President Abbie Celniker Receives Honors from Massachusetts Technology Leadership Council      Oct 19, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Third Quarter Financial Results      Oct 17, 05 08:03 ET Millennium Initiates Combination Phase I/II Trial of MLN518 in Acute Myelogenous Leukemia      Sep 13, 05 16:09 ET Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation      Sep 06, 05 16:01 ET Bear Stearns 18th Annual Healthcare Conference to Webcast Millennium Presentation      Sep 02, 05 16:01 ET NewsMakers in the Biotech Industry Conference to Webcast Millennium Presentation      Sep 01, 05 16:01 ET Thomas Weisel Partners Healthcare Tailwinds Conference 2005 to Webcast Millennium Presentation      Aug 18, 05 08:01 ET Millennium Initiates Phase II Clinical Trial to Evaluate MLN1202 in Cardiovascular Disease      Jul 28, 05 07:07 ET Millennium Reports Second Quarter 2005 Financial Results      Jul 21, 05 16:24 ET Millennium Pharmaceuticals to Webcast Conference Call on Second Quarter Financial Results      Jul 11, 05 07:01 ET Millennium Initiates Phase II Clinical Trial in Patients With Multiple Sclerosis      Jun 29, 05 07:50 ET Millennium Announces New CEO      Jun 28, 05 08:02 ET EARLY ACS Trial Designed to Reinforce Benefit of Early Use of INTEGRILIN(R) (eptifibatide) Injection in Contemporary nSTE ACS Setting      Jun 17, 05 08:01 ET Millennium Announces Appointment to Board of Directors      Jun 16, 05 08:01 ET New England Journal of Medicine Publishes Studies of VELCADE(R) (bortezomib) for Injection in Multiple Myeloma and MLN02 in Ulcerative Colitis      Jun 13, 05 08:04 ET VELCADE(R) (bortezomib) for Injection Showed Positive Activity Across a Variety of Lymphomas      Jun 10, 05 16:01 ET Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference to Webcast Millennium Presentation      Jun 08, 05 07:01 ET Two New Studies in the British Journal of Haematology Show Potential Role of VELCADE(R) (Bortezomib) for Injection in Treating Patients with Front-Line Multiple Myeloma      May 17, 05 08:03 ET New Front-Line Data at ASCO in Multiple Myeloma Support Important Role of VELCADE(R) (bortezomib) for Injection      May 14, 05 08:01 ET Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented      May 11, 05 16:01 ET Banc of America Securities Health Care Conference 2005 to Webcast Millennium Presentation      May 09, 05 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event      May 05, 05 16:56 ET Robert W. Baird & Co. 2005 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation      Apr 28, 05 16:01 ET Millennium Pharmaceuticals to Webcast 2005 Annual Meeting of Stockholders      07:05 ET Millennium Reports First Quarter VELCADE(R) (bortezomib) for Injection Sales Up 51%, R&D Expenses Down 11% Compared to First Quarter 2004   Apr 25, 05 08:02 ET VELCADE(R) (bortezomib) for Injection Phase II Clinical Trial Initiated in Lung Cancer      Apr 21, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on First Quarter Financial Results      Apr 13, 05 08:12 ET Studies of VELCADE(R) (bortezomib) for Injection Show Emerging Role as Cornerstone of Multiple Myeloma Care      08:06 ET Studies of VELCADE(R) (bortezomib) for Injection Show Emerging Role as Cornerstone of Multiple Myeloma Care      Apr 08, 05 08:18 ET Key Data on VELCADE(R) (Bortezomib) for Injection in Front-Line Studies and Beyond at the International Multiple Myeloma Workshop      Mar 28, 05 16:01 ET CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference to Webcast Millennium Presentation      11:38 ET Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for Injection in Second-Line Multiple Myeloma      Mar 25, 05 15:10 ET FDA Grants Full Approval for VELCADE(R) (Bortezomib) for Injection; Claims Include Survival Advantage and Use in Second-Line Multiple Myeloma      Mar 24, 05 16:52 ET Lehman Brothers Eighth Annual Global Healthcare Conference to Webcast Millennium Presentation      Mar 22, 05 16:01 ET Citigroup Smith Barney Healthcare Conference to Webcast Millennium Presentation      Mar 14, 05 08:04 ET Millennium Announces Senior Executive Appointments --Expands Key Leadership Roles and Promotes Senior Leaders From Within--   Mar 10, 05 16:01 ET SG Cowen & Co. 25th Annual Healthcare Conference to Webcast Millennium Presentation   08:02 ET Velcade(R) (bortezomib) for Injection Multiple Myeloma Retreatment Clinical Trial Initiated   Mar 08, 05 16:01 ET Data Support the Positive Clinical Benefits of GP IIb-IIIa Inhibitors and INTEGRILIN(R) (eptifibatide) Injection      Mar 07, 05 16:01 ET Millennium Achieves Milestone Payments of Approximately $40 Million      Mar 01, 05 08:03 ET INTEGRILIN(R) (Eptifibatide) Injection When Added to Clopidogrel Provided Superior Platelet Inhibition and Reduced Heart Muscle Death, Based on the Release of Cardiac Necrosis Biomarkers      Feb 22, 05 16:01 ET Millennium to Participate in the SunTrust Robinson Humphrey 'Off the Cuff' Therapeutics Conference      Feb 20, 05 08:01 ET Millennium Announces Promising Findings from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial      Feb 03, 05 08:02 ET Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation      Feb 01, 05 08:02 ET VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients With Non-Hodgkin's Lymphoma      Jan 27, 05 07:03 ET Millennium Reports Year End and Fourth Quarter 2004 Financial Results      Jan 25, 05 08:04 ET Millennium and UCB Pharma Enter Into Agreement to Collaborate on Two Biotherapeutic Inflammation Programs      Jan 20, 05 16:01 ET Millennium Pharmaceuticals to Webcast Conference Call on Fourth Quarter and Full-Year 2004 Financial Results      Jan 10, 05 08:09 ET Millennium to Highlight 2004 Accomplishments and 2005 Outlook at JPMorgan 23rd Annual Healthcare Conference      08:04 ET VELCADE(R) (bortezomib) for Injection Phase III Clinical Trial Initiated In Patients With Newly Diagnosed Multiple Myeloma      Jan 06, 05 16:01 ET Millennium to Webcast Business Update Conference Call on January 10, 2005 in Advance of JP Morgan Conference Presentation      Jan 05, 05 16:01 ET JP Morgan 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Dec 20, 04 08:32 ET Millennium Announces Changes in Commercial Management and Board of Directors      Dec 15, 04 08:01 ET Millennium Receives Top Industry Awards      Dec 14, 04 08:01 ET Groundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis Disease Severity      Dec 06, 04 20:30 ET VELCADE(R) (Bortezomib) for Injection Studies Results Indicate Potential Utility Across the Multiple Myeloma Treatment Paradigm      19:42 ET VELCADE(R) (bortezomib) for Injection Continues to Provide Responses In Several Subtypes of Non-Hodgkin's Lymphoma      Dec 01, 04 08:24 ET FDA Accepts sNDA Filing with Priority Review for VELCADE(R) (bortezomib) for Injection to Treat Second-Line Multiple Myeloma      08:02 ET New Data on VELCADE(R) (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting      Nov 29, 04 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event Monday, December 6, 2004 7:00 P.M. PST (10:00 P.M. EST)      Nov 23, 04 16:01 ET Lazard Annual Life Sciences Conference to Webcast Millennium Presentation      Nov 09, 04 16:16 ET Millennium Announces Webcast of R&D Day 2004 Presentations      Nov 08, 04 08:04 ET New Clinical Trial Data Showed the Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone      Nov 06, 04 18:15 ET New Data Reveal Clinical Differences Between INTEGRILIN (R) (Eptifibatide) Injection and Bivalirudin      Nov 03, 04 16:07 ET CIBC World Markets Fifteenth Annual Healthcare Conference to Webcast Millennium Presentation      Nov 02, 04 16:15 ET FDA Grants VELCADE(R) (bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma      Oct 28, 04 08:51 ET Millennium Reports Third Quarter 2004 Financial Results;      07:02 ET Millennium Reports Third Quarter 2004 Financial Results;      Oct 20, 04 16:13 ET Millennium Pharmaceuticals to Webcast Conference Call on Third Quarter 2004 Financial Results      Oct 18, 04 08:02 ET Millennium Pharmaceuticals Uncovers Genetic Clues to Rheumatoid Arthritis      Oct 14, 04 16:01 ET Millennium Files Post-Effective Amendment to S-3 Registration Statement      Oct 05, 04 16:01 ET Millennium Appoints New General Counsel      Sep 29, 04 08:25 ET Millennium Files Supplemental New Drug Application for VELCADE(R) (Bortezomib) for Injection for the Treatment of Patients with Second-Line Multiple Myeloma      Sep 20, 04 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Presentation      Sep 14, 04 16:01 ET Banc of America Securities 34th Annual Investment Conference to Webcast Millennium Presentation      Sep 07, 04 16:01 ET Newsmakers in the Biotech Industry Conference to Webcast Millennium Presentation      Aug 18, 04 07:59 ET VELCADE(R) (bortezomib) for Injection Named Oncology Compound of the Year at the 2004 Pharmaceutical Achievement Awards      Jul 29, 04 12:10 ET Millennium Appoints Marsha Fanucci Chief Financial Officer      Jul 22, 04 07:02 ET Millennium Reports Second Quarter 2004 Financial Results      Jul 16, 04 08:00 ET Millennium Pharmaceuticals to Webcast Conference Call on Second Quarter 2004 Financial Results      Jun 23, 04 08:01 ET Millennium and GlaxoSmithKline Announce INTEGRILIN(R) (Eptifibatide) Injection Licensing Agreement for Europe      Jun 06, 04 14:00 ET Millennium Announces Findings From a Phase I Clinical Trial of MLN2704 in Progressive, Metastatic Hormone-Refractory Prostate Cancer      09:01 ET VELCADE(R) (Bortezomib) for Injection Shows Promising Activity in Two Phase II Studies of Patients with Previously Untreated Multiple Myeloma      Jun 05, 04 11:01 ET VELCADE(R) (Bortezomib) for Injection Data Show a Significant Improvement In Survival in Patients With Relapsed Multiple Myeloma      Jun 02, 04 16:01 ET Goldman Sachs Twenty Fifth Annual Global Healthcare Conference to Webcast Millennium Presentation      07:59 ET Millennium Acquires Rights to Novel Proteasome Inhibitors and Related Synthesis Techonology      Jun 01, 04 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society Of Clinical Oncology Investor Event      07:19 ET Millennium and Schering-Plough Initiate Clinical Trial With INTEGRILIN(R) (eptifibatide) Injection in Early Use Acute Coronary Syndrome Setting      May 17, 04 16:01 ET Millennium Announces VELCADE(R) (bortezomib) for Injection has Significantly Extended Survival in Phase III (APEX) Trial of Patients with Relapsed Multiple Myeloma      May 13, 04 16:01 ET Banc of America Securities Health Care Conference 2004 to Webcast Millennium Presentation      07:59 ET Millennium Initiates Phase II Clinical Trial With VELCADE and Rituximab in Patients With Indolent Non-Hodgkin's Lymphoma      Apr 30, 04 16:01 ET Millennium Pharmaceuticals to Webcast 2004 Annual Meeting of Stockholders      Apr 28, 04 16:04 ET Millennium Reports First Quarter 2004 Financial Results      Apr 27, 04 12:15 ET European Commission Grants Marketing Authorization to Millennium for VELCADE(R) (Bortezomib)      Apr 22, 04 16:01 ET Millennium Pharmaceuticals To Webcast Conference Call on First Quarter 2004 Financial Results   Apr 01, 04 08:03 ET Millennium and NCI Collaborate to Investigate Role of ACE2 in Connection with SARS   Mar 17, 04 07:59 ET Millennium Announces FDA Selection of MLN2704 for Continuous Marketing Application Pilot 2 Program      Mar 02, 04 16:01 ET SG Cowen 24th Annual Health Care Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Feb 25, 04 16:01 ET Lehman Brothers Seventh Annual Global Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Jan 27, 04 16:04 ET Millennium Reports Year End and Fourth Quarter 2003 Financial Results      Jan 22, 04 11:50 ET VELCADE(TM) (Bortezomib) Recommended for European Marketing Approval      Jan 20, 04 16:01 ET Millennium Pharmaceuticals, Inc. to Webcast Conference Call on Year End And Fourth Quarter 2003 Financial Results on January 28, 2004      Jan 12, 04 08:33 ET Millennium to Highlight 2004 Financial Outlook and Goals at JPMorgan Healthcare Conference      Jan 06, 04 12:07 ET Millennium Responds to Media Reports Related to Closure Of Phase II VELCADE Colorectal Trial      Jan 05, 04 13:47 ET JP Morgan 22nd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Dec 22, 03 08:07 ET Millennium Initiates Phase I Clinical Trial of MLN3897   Dec 15, 03 05:25 ET Independent Committee Recommends Early End to Confirmatory Phase III VELCADE Trial Based on Achieving Statistically Significant Improvement in Primary Endpoint      Dec 11, 03 14:00 ET Early Research Advances Field of Proteasome Biology      Dec 09, 03 16:01 ET Preliminary Study Results of VELCADE(TM) (bortezomib) for Injection Combined With Thalidomide Demonstrated Anti-Tumor Activity in Patients With Advanced Multiple Myeloma      Dec 08, 03 18:30 ET New Phase II Findings Support Potential Role of VELCADE(TM) (bortezomib) for Injection in Patients With Non-Hodgkin's Lymphoma      08:03 ET Preliminary Phase II Results With VELCADE(TM) (Bortezomib) For Injection Demonstrated Activity In Patients With Previously Untreated Multiple Myeloma      Dec 04, 03 07:59 ET FDA Grants Millennium Fast Track Status for MLN2704      Dec 03, 03 08:19 ET New Data on VELCADE(TM) (bortezomib) for Injection to be Presented at Upcoming American Society of Hematology Meeting      Dec 01, 03 16:01 ET Millennium Announces Webcast of American Society of Hematology Investor Event      Nov 04, 03 17:09 ET CIBC World Markets Fourteenth Annual Healthcare Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Oct 27, 03 08:24 ET Millennium and Bayer's Successful Research Collaboration Concludes      Oct 15, 03 16:11 ET Millennium Reports Third Quarter 2003 Financial Results      Oct 14, 03 07:59 ET Millennium Initiates Phase II Clinical Trial With MLN1202 in Patients With Rheumatoid Arthritis      Oct 09, 03 16:02 ET Millennium Pharmaceuticals Announces Webcast Of Analyst And Investor Day Presentations      08:03 ET Millennium Initiates Phase I/II Clinical Trial of MLN2704 in Patients with Metastatic Androgen-Independent Prostate Cancer      Sep 26, 03 07:59 ET Millennium Announces Assignment of Medicare Code for VELCADE(TM) (bortezomib) for Injection      Sep 22, 03 16:01 ET UBS Global Life Sciences Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation      Sep 19, 03 15:38 ET Correction to Press Release: New Data Show Early Use of Anti-Platelet Therapy Reduced Combined Death or Subsequent Heart Attacks in High-Risk Heart Attack Patients      Sep 17, 03 15:36 ET New Data Show Early Use Of Anti-Platelet Therapy Reduced Combined Death Or Subsequent Heart Attacks In High-Risk Heart Attack Patients      Aug 28, 03 16:01 ET Newsmakers in the Biotech Industry Conference to Webcast Millennium Pharmaceuticals, Inc. Presentation   Aug 22, 03 08:11 ET Julian Adams, Ph.D. to Join Infinity as Chief Scientific Officer   08:09 ET Millennium Announces Changes in R&D Management      Jul 22, 03 07:31 ET Millennium Reports Second Quarter 2003 Financial Results      Jul 16, 03 16:04 ET Millennium to Webcast Conference Call on Second Quarter 2003 Financial Results on July 22, 2003      Jul 10, 03 07:59 ET Millennium Announces Changes in Senior Management      Jul 03, 03 02:00 ET Millennium and Xenova Initiate Phase I Clinical Trial Of MLN944      Jul 02, 03 08:00 ET Millennium Initiates Phase II Clinical Trial with VELCADE(TM) (Bortezomib) for Injection in Patients with Relapsed or Refractory Mantle Cell Lymphoma      Jun 30, 03 16:02 ET Millennium Enters Into Commercialization and Development Agreement With Ortho Biotech Products, L.P., for VELCADE(TM) (Bortezomib) For Injection      Jun 25, 03 17:00 ET Velcade(TM) (Bortezomib) for Injection Phase II (Summit) Multiple Myeloma Study Results Published in the New England Journal of Medicine   Jun 05, 03 09:30 ET Millennium Announces Restructuring      Jun 04, 03 16:01 ET Goldman Sachs Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Jun 03, 03 09:01 ET Millennium Announces Promising Early Study Results With VELCADE(TM) (bortezomib) For Injection Combined With Doxil in Patients With Advanced Multiple Myeloma      Jun 02, 03 13:28 ET Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE(TM) (Bortezomib) For Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors      May 27, 03 12:44 ET Millennium Pharmaceuticals Announces Webcast of American Society of Clinical Oncology Investor Event      May 21, 03 16:18 ET In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo      May 20, 03 13:55 ET Millennium Ships VELCADE(TM) (bortezomib) for Injection Within Six Days of FDA Approval      May 13, 03 19:18 ET Millennium to Webcast Conference Call on Recent FDA Approval of Velcade(TM) (bortezomib) for Injection on May 14, 2003      18:35 ET FDA Approves VELCADE(TM) (bortezomib) for Injection for the Treatment of Relapsed and Refractory Multiple Myeloma      May 06, 03 16:01 ET Robert W. Baird 2003 Growth Stock Conference to Webcast Millennium Pharmaceuticals Presentation   Apr 29, 03 16:11 ET Millennium Announces Completion of Cash Offers For 4.50% and 5.00% Convertible Notes      16:02 ET 2003 Deutsche Bank Securities Health Care Conference to Webcast Millennium Pharmaceuticals Presentation      Apr 24, 03 16:12 ET Millennium Pharmaceuticals to Webcast 2003 Annual Meeting of Stockholders      16:12 ET Morgan Stanley 1st Annual Healthcare Unplugged Conference to Webcast Millennium Pharmaceuticals Presentation      Apr 23, 03 16:02 ET CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference to Webcast Millennium Pharmaceuticals Presentation      Apr 21, 03 07:59 ET Millennium Confirms Terms of Convertible Notes      Apr 15, 03 16:01 ET Millennium Reports First Quarter 2003 Financial Results   Apr 14, 03 08:32 ET Groundbreaking Research Identifies Molecular Pathway Underlying Key Infection-Fighting Mechanism   Apr 09, 03 16:30 ET Millennium to Webcast Conference Call on First Quarter 2003 Financial Results on April 15, 2003      Mar 31, 03 07:59 ET Millennium Commences Required Cash Offers for Convertible Notes      Mar 20, 03 16:02 ET Banc of America Securities Healthcare Conference 2003 to Webcast Millennium Pharmaceuticals Presentation      Mar 13, 03 16:01 ET SG Cowen 23rd Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentations      Mar 10, 03 11:03 ET FDA Accepts for Review NDA Filing and Grants Priority Review for VELCADE(TM) (bortezomib) for Injection      Feb 27, 03 16:03 ET Lehman Brothers Sixth Annual Global Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Feb 25, 03 07:59 ET EMEA Accepts Marketing Authorization Application For Bortezomib (VELCADE(TM)) 3.5mg Powder For Solution For Injection      Feb 24, 03 16:00 ET Lehman Brothers Sixth Annual Global Healthcare Conference To Webcast Millennium Pharmaceuticals Presentation      Feb 19, 03 16:09 ET Bio CEO & Investor Conference 2003 to Webcast Millennium Pharmaceuticals Presentation      Feb 04, 03 16:21 ET Millennium Seeks European Regulatory Approval for Bortezomib (VELCADE(TM)) 3.5mg Powder for Solution for Injection      Jan 28, 03 16:13 ET Millennium Reports Year End and Fourth Quarter 2002 Financial Results      Jan 22, 03 16:33 ET Millennium to Webcast Conference Call on Year End and Fourth Quarter 2002 Financial Results On January 28, 2003      07:59 ET Millennium Submits New Drug Application for VELCADE(TM) (Bortezomib) for Injection   Jan 15, 03 08:20 ET Millennium Initiates Phase II Clinical Trial With Velcade(TM) (Bortezomib) for Injection fn Patients With Advanced Non-Small Cell Lung Cancer   Jan 06, 03 08:57 ET Millennium Highlights 2003 Financial Outlook and Goals at JP Morgan H&Q Healthcare Conference      Dec 30, 02 16:54 ET JP Morgan H&Q 21st Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      08:01 ET Millennium Initiates Phase II Clinical Trial With VELCADE(TM) (Bortezomib) for Injection in Patients With Colorectal Cancer      Dec 20, 02 07:59 ET Millennium Initiates Phase I Clinical Trial of MLN1021, A Novel, Oral Factor Xa Inhibitor   Dec 11, 02 14:00 ET Millennium Discovers Markers Associated With Chemotherapy Response in Breast Cancer Patients      Dec 09, 02 10:42 ET Final Phase II Data Presented from the VELCADE(TM) (bortezomib) for Injection Summit Trial in Patients with Advanced Stage Multiple Myeloma      10:38 ET New Data From Velcade(TM) (Bortezomib) For Injection Crest Study Indicate Responses In Patients With Relapsed Multiple Myeloma      Dec 04, 02 16:02 ET Millennium Plans To Submit a New Drug Application for Velcade(TM) (Bortezomib) for Injection      16:01 ET Millennium Announces Changes in Senior Management      16:01 ET Millennium To Host Conference Call And Webcast      Dec 02, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event   Nov 21, 02 07:59 ET Millennium Initiates Phase I Clinical Trial of MLN2704 in Patients With Metastatic Androgen-Independent Prostate Cancer      Nov 19, 02 08:59 ET Millennium Announces Cardiovascular Research Collaboration With The Cleveland Clinic      Nov 17, 02 17:23 ET New Data Show Hospital Adherence to Chest Pain Guidelines Reduced Risk of Death by Nearly Half      Nov 12, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of American Heart Association Scientific Sessions Investor Event Presentations      Nov 11, 02 09:06 ET Millennium Announces Initiation of Phase III Clinical Trial of INTEGRILIN(R) (eptifibatide) Injection in Heart Attack Patients      Nov 07, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation At Credit Suisse First Boston Health Care Conference      Nov 04, 02 16:55 ET Millennium Pharmaceuticals Announces Webcast of Presentation at SG Cowen Global 2002 Health Care Conference      Oct 30, 02 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at CIBC World Markets 13th Annual Health Care Conference      Oct 22, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at MassOpps 4th Annual Investor Conference   Oct 15, 02 16:04 ET Millennium Reports Third Quarter 2002 Financial Results      Oct 09, 02 16:01 ET Millennium to Webcast Conference Call on Third Quarter 2002 Financial Results on October 15, 2002      Oct 03, 02 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation At UBS Warburg Global Life Sciences Conference      Sep 16, 02 08:04 ET Millennium Announces Phase II Data for MLN02 in Crohn's Disease      Sep 10, 02 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Bear Stearns 15th Annual Health Care Conference      Jul 16, 02 16:02 ET Millennium Reports Second Quarter 2002 Financial Results      Jul 15, 02 07:58 ET Millennium Discontinues Oral MLN977 Program      Jul 10, 02 16:00 ET Millennium Pharmaceuticals Announces Webcast Of Oncology Franchise Review Presentations      12:00 ET Millennium to Webcast Conference Call On Second Quarter 2002 Financial Results On July 16, 2002      Jun 11, 02 16:25 ET Millennium Initiates Pivotal Phase III Clinical Trial Comparing VELCADE(TM) (bortezomib) for Injection with High-Dose Dexamethasone in Patients with Multiple Myeloma      Jun 05, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast Of Presentation at the Goldman Sachs 23rd Annual Global Healthcare Conference      08:45 ET FDA Grants Millennium's MLN341 and MLN518 Fast Track Status      May 29, 02 08:00 ET Millennium Initiates Phase I Clinical Trial of MLN518 In Acute Myeloid Leukemia (AML)      May 28, 02 07:59 ET Millennium Pharmaceuticals Announces Webcast of Presentation At the Needham & Company First Annual Biotechnology Conference      May 21, 02 09:30 ET Millennium Researchers Announce Preliminary Phase I Findings of Proteasome Inhibitor MLN341 Against Several Solid Tumor Types      May 20, 02 09:30 ET Preliminary Phase II Data on Millennium's Proteasome Inhibitor MLN341 Hold Promise for Patients With Multiple Myeloma      Apr 30, 02 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the Deutsche Bank Securities 27th Annual Health Care Conference      Apr 29, 02 15:22 ET Millennium Announces Completion of Cash Offer For Notes Assumed in COR Therapeutics Merger      Apr 24, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference      Apr 23, 02 08:02 ET Millennium Pharmaceuticals Announces Webcast of Panel Discussion at The Thomas Weisel Healthcare Tailwinds Conference      Apr 22, 02 17:57 ET Millennium Amends Notes Assumed in COR Therapeutics Merger      Apr 16, 02 16:16 ET Millennium Reports First Quarter 2002 Financial Results      08:17 ET Millennium Pharmaceuticals and Ingenuity Systems Announce Groundbreaking Knowledge Management Collaboration      Apr 12, 02 12:00 ET Millennium to Webcast Conference Call on First Quarter 2002 Financial Results on April 16, 2002      Apr 09, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at The Nasdaq European Life Sciences Forum      Apr 08, 02 08:06 ET Millennium Researchers Announce Preclinical Findings of its Proteasome Inhibitor MLN341 Against Several Solid Tumor Types      Mar 28, 02 16:30 ET SEC Declares Effective Registration Statement of Millennium Pharmaceuticals Related to 4.50% Convertible Senior Notes      Mar 27, 02 08:01 ET Millennium Pharmaceuticals Announces Webcast of Fourth Annual Analyst and Investor Day Presentations      Mar 14, 02 08:57 ET Millennium Announces Cash Offers for Notes Assumed in COR Therapeutics, Inc. Merger      07:00 ET Millennium and PAION to Collaborate on Stroke Program      Mar 13, 02 12:00 ET Millennium Pharmaceuticals Announces Webcast of Panel Discussion and Presentation at The Banc of America Genomics & Diagnostics Conference      Feb 15, 02 12:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the Bio CEO & Investor Conference      Feb 14, 02 16:01 ET /C O R R E C T I O N -- Millennium Pharmaceuticals/   16:00 ET Millennium's Chief Scientific Officer Appointed to National Advisory Council for Human Genome Research      12:00 ET Millennium Pharmaceuticals Announces Webcast of Panel Discussions at The Goldman Sachs Oncology Conference      Feb 12, 02 14:38 ET Shareholders Approve Merger of Millennium Pharmaceuticals and COR Therapeutics      Jan 31, 02 13:46 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the Merrill Lynch Global Drug, Device and Biotech Conference      Jan 24, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the U.S. Bancorp Piper Jaffray Health Care Conference      Jan 22, 02 16:06 ET Millennium Reports Year End 2001 Financial Results      Jan 17, 02 17:51 ET Millennium and COR Therapeutics Receive Early Hart-Scott-Rodino Clearance      Jan 15, 02 16:00 ET Millennium to Webcast Conference Call on Year End 2001 Financial Results on January 22, 2002   Jan 09, 02 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at the Wachovia Securities Integrated Oncology Conference      Jan 07, 02 08:04 ET Millennium Highlights Financial Outlook and Goals for 2002 at JPMorgan H&Q Healthcare Conference      08:01 ET Millennium Initiates Combination Oncology Trials of MLN341 with Taxotere(R)      Jan 03, 02 16:00 ET JP Morgan H&Q 20th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Dec 17, 01 07:02 ET Millennium In-Licenses Novel Oncology Program From Xenova      Dec 10, 01 14:01 ET New Phase II Data on Millennium's Proteasome Inhibitor Holds Promise For Patients With Refractory Multiple Myeloma      Dec 06, 01 07:01 ET Millennium and COR Therapeutics Agree to Merge Creating Integrated Biopharmaceutical Company      Nov 27, 01 08:01 ET Millennium and Abbott Initiate Phase I Trials of Their First Genomically-Derived Drug Target for Obesity      Nov 26, 01 12:00 ET Millennium In-Licenses Novel Target for Colorectal Cancer      12:00 ET Millennium and XOMA Enter Agreement to Collaborate on Two Vascular Inflammation Programs      Nov 20, 01 16:06 ET Millennium Pharmaceuticals Announces Webcast of Presentation At the SG Cowen Investor Conference      16:01 ET Millennium Pharmaceuticals Announces Posting of Presentation at The Robertson Stephens Healthcare Conference on its Website      Nov 02, 01 08:01 ET Millennium Researchers Announce Initial Findings of Phase I Trial of Proteasome Inhibitor for Multiple Myeloma      Nov 01, 01 16:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at CIBC World Markets Health Care Conference      Oct 29, 01 16:25 ET ILEX and Millennium Agree to Restructure Ownership in Campath(R)      Oct 24, 01 12:01 ET Millennium Pharmaceuticals Announces Webcast of Presentation at The Mass Opportunities Investor Conference      12:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at The Salomon Smith Barney Health Care Conference      09:03 ET Millennium and Affymetrix Partner to Advance Gene Expression Array Technology      Oct 19, 01 08:01 ET Millennium and New York Weill Cornell Medical Center Researchers Report Interim Findings of Ongoing Phase I Human Clinical Trials of a Humanized Antibody Therapy for Advanced Prostate Cancer      Oct 16, 01 16:02 ET Millennium Reports Third Quarter 2001 Financial Results      08:01 ET Millennium Researchers Identify New Role for Collagenase Enzyme in Cardiovascular Disease      Oct 12, 01 12:00 ET Millennium to Webcast Conference Call on Third Quarter 2001 Financial Results on October 16, 2001      Oct 11, 01 08:01 ET Millennium Names Allan Marchington, Ph.D., Senior Vice President Of Productivity      Oct 04, 01 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation At the UBS Warburg Global Life Sciences Conference      08:01 ET Millennium Completes Enrollment of a Phase II Human Clinical Trial for LDP-341 in Multiple Myeloma      Oct 03, 01 08:03 ET Millennium Expands Proteasome Patent Estate      Sep 24, 01 12:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation At Bear Stearns Health Care 'Virtual' Conference      Sep 19, 01 07:01 ET Bayer and Millennium Expand Commitment Based on Success of Research Program and Advancements In Drug Discovery      Sep 07, 01 12:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Banc of America Securities Annual Investment Conference      12:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Bear Stearns 14th Annual Health Care Conference      Aug 13, 01 07:59 ET Aventis Pharma And Millennium Add 11 Discovery Projects To Joint Drug Development Pipeline For Inflammatory Disease      Jul 17, 01 19:02 ET Millennium and Pharsight Sign Agreement for Application Of Pharsight's Model- Based Software and Methodologies to Millennium's Lead Oncology Program   17:50 ET Millennium Reports Second Quarter 2001 Financial Results      16:07 ET Millennium and Pharsight Sign Agreement for Application Of Pharsight's Model- Based Software and Methodologies to Millennium's Head Oncology Program   Jul 12, 01 07:01 ET European Commission Grants Marketing Authorization To Millennium & ILEX Partners' MabCampath(TM) (Alemtuzumab)      Jul 11, 01 16:31 ET Millennium to Webcast Conference Call on Second Quarter 2001 Financial Results on July 18, 2001      Jun 22, 01 16:30 ET Millennium Pharmaceuticals Announces Webcast of Presentation at First Union Securities Eleventh Annual Nantucket Equity Conference      Jun 15, 01 09:04 ET Millennium Initiates Phase II Clinical Trials of LDP-341 in Chronic Lymphocytic Leukemia      Jun 14, 01 18:18 ET Millennium Initiates Combination Trials of LDP-341 With Gemcitabine and Irinotecan      Jun 13, 01 16:29 ET Millennium Promotions Strengthen Management Team and Enhance Organizational Effectiveness      Jun 12, 01 07:59 ET Millennium Initiates Phase II Clinical Trial of LDP-977 in Asthma      Jun 07, 01 07:59 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Goldman Sachs Healthcare Conference      May 08, 01 08:30 ET U.S. Food and Drug Administration Approves New Treatment, Campath(R) (alemtuzumab) Humanized Monoclonal Antibody, for Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)      May 02, 01 17:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Deutsche Banc Alex. Brown Health Care Conference      Apr 30, 01 17:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at CIBC World Markets Biotechnology Conference      Apr 19, 01 16:30 ET Millennium Names Peter F. Smith Senior Vice President of Preclinical Drug Development      Apr 17, 01 16:31 ET Millennium Reports First Quarter 2001 Financial Results      Apr 11, 01 16:30 ET Millennium to Webcast Conference Call on First Quarter 2001 Financial Results on April 18, 2001      07:59 ET Millennium and BZL Biologics Announce Agreement To Develop Antibody Therapies Against Key Target In Prostate Cancer      Apr 05, 01 17:00 ET Millennium Pharmaceuticals Adopts Shareholder Rights Plan      Apr 02, 01 16:30 ET Millennium Appoints Kenneth E. Weg, Former Vice Chairman of Bristol-Myers Squibb, to Board of Directors      Mar 30, 01 15:51 ET MabCampath(TM) (Alemtuzumab) Recommended For European Marketing Approval      07:59 ET Millennium Pharmaceuticals Announces Webcast of Third Annual Analyst and Investor Day Presentations      Mar 22, 01 07:59 ET Millennium Pharmaceuticals Announces Webcast of Presentation At Banc of America Securities Health Care Conference      Mar 13, 01 07:03 ET Millennium and Protein Design Labs Announce Agreement For Humanized Antibody Patent Rights      Mar 12, 01 07:31 ET Millennium and Abbott Laboratories Form Strategic Alliance in Metabolic Disease      Mar 05, 01 16:30 ET Millennium and ImmunoGen Form Multi-Product Antibody Collaboration   Mar 01, 01 09:18 ET Millennium Initiates Phase II Clinical Trials of LDP-341 in Multiple Myeloma   Feb 27, 01 16:59 ET Millennium Pharmaceuticals Presentation to Lehman Brothers Global Healthcare Conference to be Available by Conference Call      07:59 ET Millennium Issued Broad Patent for ACE2 Gene Which Holds Potential For Targeted Disease Management      Feb 21, 01 08:31 ET Millennium & ILEX Partners Receives Complete Response Letter From FDA for CAMPATH(R) (Alemtuzumab)      Feb 09, 01 09:10 ET Millennium Initiates Phase II Clinical Trial of LDP-02 In Ulcerative Colitis   Feb 08, 01 07:59 ET Millennium Initiates Phase II Clinical Trial of LDP-02 In Ulcerative Colitis      Feb 02, 01 16:00 ET Millennium Pharmaceuticals Announces Webcast of Presentation at Merrill Lynch Global Pharmaceutical Device and Biotechnology Conference      Jan 23, 01 16:14 ET Millennium Reports Year End 2000 Financial Results - Provides 2001 Financial Guidance -      Jan 17, 01 16:30 ET Millennium to Webcast Conference Call on Year End 2000 Financial Results on January 24, 2001      Jan 12, 01 08:01 ET Study Validates That Melastatin(TM) Gene Assists With Prognosis Of Melanoma      Jan 10, 01 03:00 ET Millennium and Bayer Announce Genome-Derived Oncology Drug Candidate Selected for First Human Studies      Jan 09, 01 08:01 ET Millennium and Wyeth-Ayerst Identify Preclinical Antibacterial Compound   Jan 08, 01 02:00 ET Millennium and Roche Form Alliance in the Area of Rheumatoid Arthritis Diagnostics      Jan 05, 01 08:01 ET Chase H&Q 19th Annual Healthcare Conference to Webcast Millennium Pharmaceuticals Presentation      Jan 04, 01 08:02 ET Millennium Names Paul Hamelin Senior Vice President of Commercial Operations      Dec 12, 00 07:59 ET Millennium to Webcast Conference Call Following Review of CAMPATH Data by FDA Advisory Committee      Dec 04, 00 16:30 ET Millennium's LDP(PS)-341 Inhibits Growth and Induces Death of Cancer Cells, Appears to Overcome Chemotherapy Resistance      Nov 22, 00 08:01 ET Millennium Appoints Edward Miller, CEO and Dean of Johns Hopkins Medicine, To Board of Directors      Nov 09, 00 16:30 ET Millennium's LDP-341 Demonstrates Encouraging Anti-Cancer Activity In Clinical Trials      Oct 24, 00 07:59 ET Millennium and Bayer Industrializing Drug Discovery Process Through Ongoing Successful Research Alliance      02:30 ET Millennium and Bayer Industrializing Drug Discovery Process Through Ongoing Successful Research Alliance      Oct 17, 00 17:13 ET Millennium Reports Third Quarter 2000 Financial Results      Oct 06, 00 08:01 ET Millennium Prices Offering of $704 Million of its Common Stock      Sep 29, 00 04:00 ET Millennium Offering Shares of Its Common Stock      Sep 26, 00 16:31 ET Millennium Names James A. Nash Senior Vice President of Manufacturing   Sep 07, 00 08:01 ET Millennium's Board Approves Two-For-One Stock Split      Aug 31, 00 08:07 ET Millennium Discovers ACE2, a Novel Cardiovascular Drug Target, With Potential to Lead to New Treatments      Aug 09, 00 17:00 ET Millennium Expands Global Presence Through Opening of Japan Office      Jul 28, 00 07:59 ET Millennium and Aventis Pharma Close Alliance Agreement And Begin Collaborative Work      Jul 27, 00 07:01 ET Millennium Announces Completion of Cambridge Discovery Chemistry(TM) Acquisition      Jul 18, 00 17:28 ET Millennium Reports Second Quarter 2000 Financial Results      16:50 ET Millennium Predictive Medicine and BD Enter Into Licensing Agreement In The Area of Colon Cancer Diagnostics      Jul 17, 00 16:30 ET Millennium Delivers Four Novel Central Nervous System Candidate Genes To Wyeth-Ayerst      Jul 06, 00 13:59 ET Millennium Announces Plan to Acquire Cambridge Discovery Chemistry(TM)      Jun 23, 00 02:00 ET translations, to Japan. -- WITH LOGO -- TO BUSINESS AND MEDICAL EDITORS:      Jun 15, 00 07:59 ET Millennium and Lilly Announce Extension of Discovery Research Collaboration      Jun 13, 00 07:59 ET Millennium Appoints Norman C. Selby, Health Care and Internet Business Specialist, to Board of Directors      Jun 12, 00 08:59 ET Millennium Submits Investigational New Drug Application to FDA For LDP-02 in Ulcerative Colitis      Jun 05, 00 09:14 ET Millennium and Biacore Collaborate to Develop New Drug Discovery Technology      Jun 01, 00 14:00 ET Millennium Names Susan Ward To Senior Management Team      May 24, 00 08:59 ET Millennium'S LDP-02 Demonstrates Encouraging Clinical Trial Results In Ulcerative Colitis      May 23, 00 08:59 ET Millennium Presents Clinical Trial Data on LDP-341 for Advanced Malignancies      Apr 27, 00 17:10 ET Millennium Form S-3 Filing Related to Its Convertible Notes      Apr 18, 00 17:10 ET Millennium Reports First Quarter 2000 Financial Results - Two-for-one Stock Split Effective -      Apr 07, 00 08:01 ET Christopher Mirabelli, Ph.D. to Resign From Millennium Following Completion Of His Role in Integration of LeukoSite      Mar 27, 00 08:04 ET Millennium Technology Platform Expands to Include LabChip Tools Through Collaboration with Caliper      Mar 21, 00 08:01 ET Millennium Extends Chemokine Drug Discovery Alliance With Kyowa Hakko For Inflammatory and Autoimmune Disease      Mar 20, 00 08:05 ET Millennium Extends Collaboration With MorphoSys AG to Advance an Additional Antibody Target      Mar 15, 00 08:06 ET Millennium's Commercialization Strategy Enhanced Through Wide Access to Human Genome      Mar 06, 00 17:02 ET Millennium Gains Broad Access To Human Antibody Technology Through Collaboration With Abgenix      Mar 02, 00 08:32 ET Millennium Acquires Minority Interest in Predictive Medicine Subsidiary In Pursuit of Delivering Personalized Medicine   Mar 01, 00 08:03 ET Millennium Announces Filing Related to Its Subordinated Convertible Notes   08:01 ET Millennium Receives Patent for Melastatin(TM) Relating to Determination Of Metastatic Melanoma Risk   Feb 28, 00 09:22 ET Millennium's Board Approves Two-For-One Stock Split   Feb 24, 00 07:59 ET Millennium Initiates Phase II Clinical Trial of LDP-02 in Crohn's Disease   Feb 03, 00 12:30 ET Millennium and Wyeth-Ayerst Announce The Discovery of Key Potassium Ion Channel Modulating Proteins In The Journal Nature   Feb 01, 00 08:00 ET Millennium Identifies Role of Madh6 Gene and Smad6 Protein In Cardiovascular Defects   Jan 25, 00 16:49 ET Millennium Reports Fourth Quarter and Year End 1999 Financial Results Including One-Time Acquisition Related Charges   Jan 14, 00 08:01 ET Millennium Raises $350 Million in Convertible Subordinated Debt Placement   Jan 10, 00 16:01 ET Millennium Announces Private Offering of Convertible Subordinated Notes   08:01 ET Millennium Appoints Steven Wheelwright, Productivity Expert, To Board of Directors   Jan 06, 00 17:11 ET Millennium Announces Marketing and Development Partnership With Taisho for Investigational Drug to Treat Chronic Asthma   Dec 22, 99 17:40 ET Millennium Announces the Completion of LeukoSite and Millennium BioTherapeutics Mergers      Dec 20, 99 08:02 ET Millennium Delivers Validated Target in Prostate Cancer for Screening to Eli Lilly   Dec 13, 99 07:59 ET Millennium Delivers Ninth Antibacterial Target for Screening to Wyeth-Ayerst   Dec 09, 99 05:00 ET Millennium Gains Early Access to Innovative Technology Through Relationship With Biacore   Dec 07, 99 08:46 ET Millennium Issued Broad Patent Relating to the Leptin Receptor and Body Weight Regulation   Nov 30, 99 08:01 ET Millennium and LeukoSite Receive Early Hart-Scott-Rodino Clearance   Oct 25, 99 08:02 ET Millennium Announces Extension of Antibacterial Research Collaboration With Wyeth-Ayerst   Oct 19, 99 07:59 ET Marcia Radosevich Appointed to the Board of Directors of Millennium Predictive Medicine   Oct 15, 99 08:04 ET Millennium Reports Third Quarter 1999 Financial Results   Oct 14, 99 17:58 ET Millennium Pharmaceuticals Enhances Pipeline in Antibody and Protein Therapeutics Through Merger With Millennium Biotherapeutics Subsidiary   17:58 ET Millennium and Leukosite Agree To Merge To Accelerate Millennium's Move Toward Commercialization   Oct 05, 99 16:01 ET Millennium Forms Agreements With Incyte and Lexicon Genetics For Access to Genomic Databases   Oct 04, 99 09:02 ET Millennium Pharmaceuticals Identifies A Key Mediator of Allergic Immune Response   Sep 29, 99 08:08 ET Millennium and Bayer Achieve Significant Progess in Major Research Alliance   Sep 23, 99 17:01 ET Millennium and the Whitehead Institute Identify Novel Protein Important in Fat Absorption   Aug 31, 99 09:04 ET Millennium Announces Extension of Central Nervous System Research Collaboration With Wyeth-Ayerst   Aug 19, 99 08:44 ET Millennium Delivers Eighth Antibacterial Target for Screening to Wyeth-Ayerst   Aug 16, 99 08:24 ET Millennium Appoints Joseph Bolen, Ph.D. as Vice President of Oncology   Aug 12, 99 14:45 ET Millennium Delivers Two Cancer Drug Candidate Genes to Eli Lilly   Jul 20, 99 16:31 ET Millennium Reports Second Quarter 1999 Financial Results   Jul 01, 99 09:25 ET Whitehead Functional Genomics Consortium Announces Technology Contribution To SNP Consortium   Jun 15, 99 07:59 ET Millennium Outlines Growth Strategy at Goldman Sachs Healthcare Conference   07:59 ET Millennium Receives Key U.S. Patent Related to Methods for Identifying Weight-Regulating Drugs   Jun 01, 99 09:01 ET Millennium Names 'Jack' Douglas General Counsel   May 18, 99 09:12 ET Millennium Receives U.S. Patent for Polycystic Kidney Disease Diagnostic Tests   Apr 20, 99 17:07 ET Millennium Reports First Quarter 1999 Financial Results   Mar 23, 99 06:30 ET Partners HealthCare and Millennium Establish Broad Strategic Research Collaboration   Mar 18, 99 08:01 ET Millennium Delivers Seventh Antibacterial Drug Target For Screening To Wyeth-Ayerst   Mar 10, 99 14:00 ET Millennium Clones Diet-Induced Obesity Gene   Feb 22, 99 03:00 ET Millennium Predictive Medicine and Becton Dickinson Establish Research Alliance in Diagnostics Industry   Feb 09, 99 17:40 ET Millennium Reports Fourth Quarter and Year End 1998 Financial Results   08:29 ET Millennium Awarded U.S. Patent Relating to Methods for Discovering New Obesity Drugs   Feb 02, 99 08:59 ET Millennium Awarded Broad U.S. Patent Covering Methods For Identifying Antimicrobial Drug Targets   Jan 12, 99 10:06 ET Millennium Extends Three Pharmaceutical Corporate Partnerships   Jan 05, 99 16:55 ET Millennium Announces Several Key Management Appointments Supporting Advancement Toward Commercialization   Dec 22, 98 08:59 ET Millennium Awarded U.S. Patent for Two Novel Caspase Genes   Dec 21, 98 09:06 ET Millennium BioTherapeutics and Harvard Medical School Develop Unique Approach to Streamline Collaboration and Share Novel Genes   08:56 ET Millennium Delivers Two Cardiovascular Drug Targets For Screening To Eli Lilly   Dec 15, 98 08:30 ET Millennium Awarded Two U.S. Patents Covering Novel Genes Involved In TGF-beta Signaling Pathways   Dec 14, 98 08:55 ET Millennium Delivers Two Cardiovascular Drug Targets For Screening To Eli Lilly   Nov 11, 98 09:17 ET Millennium Receives $130 Million In License Fees And Equity Payments From Alliance With Bayer AG   Nov 09, 98 18:01 ET Mayo Clinic and Millennium Predictive Medicine Establish Strategic Alliance   Nov 04, 98 08:37 ET Millennium Delivers Sixth Antibacterial Drug Target For Screening To Wyeth-Ayerst   Oct 20, 98 17:38 ET Millennium Reports Third Quarter 1998 Financial Results   Sep 23, 98 05:00 ET Millennium Reaches Over $1 Billion in Total Pharmaceutical Alliance Funding   05:00 ET Millennium and Bayer Form World's Largest Drug Discovery Alliance In the Pharmaceutical Industry   Sep 01, 98 08:30 ET Millennium Awarded Patent for Type 2 Diabetes Prognostic and Diagnostic Test   Aug 25, 98 07:59 ET Millennium Awarded U.S. Patent Covering A Novel Drug Discovery Method For Type 2 Diabetes Therapeutics   Aug 18, 98 08:46 ET Millennium Delivers Antibacterial Drug Target For Screening To Wyeth-Ayerst   Aug 11, 98 16:42 ET Millennium Reports Second Quarter 1998 Financial Results   Aug 10, 98 09:20 ET Millennium Aligns With Two Key Biomedical Research Institutions As Part Of Broad Strategy For Genomics-Based Drug Discovery And Development   09:19 ET Millennium and M. D. Anderson Cancer Center Establish Clinical Collaboration   09:19 ET Millennium and the University of Pittsburgh Announce Tissue Bank Collaboration   Jul 13, 98 09:01 ET Millennium and Wyeth-Ayerst Identify Novel Gene Implicated In Disorders of The Central Nervous System   Jun 30, 98 09:00 ET Millennium Achieves Research Milestone in Obesity   Jun 02, 98 17:14 ET Millennium Awarded U.S. Patent Covering Novel Methods for Identifying Drug Discovery Targets   May 19, 98 10:30 ET Millennium Predictive Medicine Announces Addition of Key New Employees   Apr 29, 98 17:27 ET Millennium Reports First Quarter 1998 Financial Results   10:44 ET Millennium Biotherapeutics, Inc. Announces Appointment of Key New Employees   Apr 21, 98 06:00 ET Millennium Pharmaceuticals, Inc. Awarded Composition of Matter Patent For UCPH Gene   06:00 ET Millennium Pharmaceuticals, Inc. and Hoffmann-La Roche Achieve Research Milestone in Obesity   Apr 16, 98 06:00 ET Millennium Pharmaceuticals, Inc. Identifies Key Mechanism For Regulating Plasma Levels of HDL or 'Good' Cholesterol   Apr 15, 98 05:59 ET Millennium Pharmaceuticals, Inc. Delivers Antibacterial Drug Target For Screening To Wyeth-Ayerst   Feb 24, 98 06:00 ET Millennium Pharmaceuticals, Inc. Awarded Its First U.S. Patent In Immunology Field   Feb 16, 98 16:29 ET Millennium Reports Fourth Quarter And Year End 1997 Financial Results   Jan 15, 98 05:55 ET Millennium Pharmaceuticals, Inc. Announces Appointment of Chris Sander, Ph.D.   Jan 13, 98 05:59 ET Millennium Pharmaceuticals, Inc. Awarded its First Patent in Predictive Medicine   Jan 08, 98 12:54 ET Millennium Pharmaceuticals, Inc. Announces Appointment of Key New Employees   Dec 16, 97 14:20 ET Millennium Pharmaceuticals, Inc. Announces Expansion of Antifungal Collaboration with Pfizer   Dec 02, 97 05:59 ET Millennium Pharmaceuticals Launches New Predictive Medicine Subsidiary   Oct 28, 97 06:00 ET Millennium Reports Third Quarter 1997 Financial Results   06:00 ET Monsanto and Millennium Enter Major Genomics Alliance   Oct 14, 97 09:05 ET /C O R R E C T I O N -- Millennium Pharmaceuticals, Inc./   Oct 13, 97 09:06 ET Millennium Pharmaceuticals, Inc. Appoints Clare Midgley Vice President, Corporate Communications   05:59 ET Millennium Pharmaceuticals, Inc. Appoints Clare Midgley Vice President, Corporate Communications   Oct 09, 97 05:59 ET Millennium Pharmaceuticals, Inc. Delivers Three Antibacterial Drug Targets To Wyeth-Ayerst   Oct 07, 97 05:59 ET Millennium Pharmaceuticals, Inc. Receives U.S. Patent For Human Melanoma Gene   Sep 29, 97 05:59 ET Millennium Pharmaceuticals, Inc. Announces Extension of Collaboration With Eli Lilly and Company   Sep 04, 97 12:28 ET Millennium Pharmaceuticals, Inc. Appoints Six World-Renowned Scientists To Its Scientific Advisory Board   Aug 19, 97 06:29 ET Millennium Pharmaceuticals, Inc. Reports on Novel Class of Proteins That Blocks TGF-Beta Signaling   Jul 31, 97 07:58 ET Millennium Pharmaceuticals, Inc. Appoints Kenneth J. Conway, President, Predictive Medicine   Jul 25, 97 05:59 ET Millennium Reports Second Quarter 1997 Financial Results   Jul 08, 97 06:01 ET Millennium Pharmaceuticals, Inc. Awarded U.S. Patent For Tub Genes   Jun 27, 97 09:09 ET Millennium Pharmaceuticals Reports on Protein That Blocks TGF-Beta Signaling   Jun 03, 97 11:18 ET Millennium Pharmaceuticals Receives U.S. Patent For Novel Melanoma Gene   May 29, 97 06:30 ET Millennium Biotherapeutics And Eli Lilly Enter Into Collaboration To Develop And Commercialize Therapeutic Proteins   06:30 ET Millennium Pharmaceuticals Establishes Subsidiary, Millennium Biotherapeutics, Inc., To Develop And Commercialize Biotherapeutic Products   Apr 25, 97 06:59 ET Millennium and Roche Report Publication in the Journal Diabetes on the Discovery of a Gene Implicated in Weight Modulation   06:58 ET Millennium Reports First Quarter 1997 Financial Results   Apr 16, 97 10:01 ET Millennium Pharmaceuticals, Inc. Appoints Nick Galakatos, Ph.D. Vice President of New Businesses   Mar 28, 97 14:19 ET Millennium Pharmaceuticals, Inc. Announces Key Management Changes   Mar 25, 97 11:00 ET Millennium Pharmaceuticals Announces Issuance of Two Patents Related to Its Drug Discovery Program   10:58 ET /C O R R E C T I O N -- Millennium Pharmaceuticals/   09:56 ET Millennium Pharmaceuticals Announces Issuance of Two Patents Related to Its Drug Discovery Program   Mar 12, 97 07:01 ET Millennium Pharmaceuticals Achieves Successful Installation of Bioinformatics Software Platform at American Home Products   Mar 07, 97 07:56 ET Millennium Receives Notice Of Allowance For Obesity Patent Application Covering UCPH   Feb 11, 97 10:01 ET Millennium Reports 1996 Financial Results and Announces Completion of Merger with ChemGenics Pharmaceuticals   09:42 ET Millennium Reports 1996 Financial Results and Announces Completion of Merger with ChemGenics Pharmaceuticals   Jan 20, 97 16:42 ET Millennium Pharmaceuticals and ChemGenics Pharmaceuticals Agree to Merge   Jan 08, 97 14:19 ET Millennium/Roche Collaboration Results in the Identification of a Novel Weight Regulation Pathway   Dec 04, 96 08:08 ET Millennium Announces Genetics-Based Atherosclerosis Target is Ready for Drug Candidate Screening   Nov 21, 96 09:08 ET Millennium and Roche Announce Achievement of Research Milestone   09:06 ET Millennium and Roche Announce Achievement of Research Milestone   Oct 24, 96 08:03 ET Millennium Pharmaceuticals, Inc. Reports Third Quarter 1996 Financial Results   Oct 09, 96 07:59 ET Millennium Pharmaceuticals, Inc. Announces Key Additions to Staff